Syndax Pharmaceuticals Inc (SNDX) Actualités

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML...

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Dec. 3, 2024 WALTHAM, Mass...

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 27, 2024 WALTHAM, Mass., Nov. 27...

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or...

Form 8-K - Current report

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire WALTHAM, Mass., Nov. 5, 2024 –  New revumenib and...

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5...

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting PR Newswire WALTHAM, Mass., Nov. 5, 2024 – New monotherapy...

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ PR Newswire WALTHAM, Mass. and NEW...